Immunovia Q2 FY26 operating loss widens to SEK 22.8 million; net sales more than quadruple to SEK 381,000

Reuters2026/08/06 06:36

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Immunovia posted Q2 net sales of SEK 381,000, more than tripling from SEK 90,000 a year earlier.
Operating loss widened to SEK 22.8 million from SEK 20.1 million; EPS was SEK -0.03 versus SEK -0.14.
Operating cash flow was SEK -20.6 million versus SEK -18.1 million; cash burn ran at SEK 7.0 million per month, below prior guidance.
Cash and cash equivalents rose to SEK 34.9 million from SEK 29.3 million at quarter-end.
PancreaSure uptake accelerated with six new high-risk surveillance centers; 10 of the top 20 U.S. cancer hospitals have ordered tests since launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovia AB published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Immunovia Q2 FY26 operating loss widens to SEK 22.8 million; net sales more than quadruple to SEK 381,000

You may also like

Crypto prices